A Phase 3 interventional study of Daprodustat in Anaemia, sponsored by GlaxoSmithKline. Completed at 4 sites in 2 countries. Open to participants aged 3 Months to 17 Years. Per ClinicalTrials.gov, last updated 2025-11-10.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 30th largest by enrollment, is one of 2 that started in 2023, is one of 9 in phase 3, and was the 28th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 3 Months to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 35th largest by enrollment, is the only one that started in 2023, is one of 10 in phase 3, and was the 35th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an international, multicenter trial, evaluating pharmacokinetics (PK) (4 weeks), safety (52 weeks), and hemoglobin (Hgb) response (52 weeks) to daprodustat in children and adolescent participants with anemia associated with chronic kidney disease (CKD) incorporating 2 independent sub-trials (Non dialysis [ND] and Dialysis [D]). This study will enroll participants with anemia associated with CKD, in 2 distinct sub-populations differing only by their CKD stage and dialysis requirement (ND: CKD stage 3 to 5 not yet receiving dialysis and D: CKD stage 5d undergoing peritoneal dialysis [PD] or hemodialysis [HD]).
The maximum duration of the study will be approximately 60 weeks, including Screening period (up to 4 weeks), treatment period (52 weeks), and follow-up period (4 weeks).
Outcome measures are identical for the ND and D sub-trials, but will be separately assessed in each sub- trials, overall and within each age subgroups (12 to less than [\<] 18 years, 6 to \<12 years, 2 to \<6 years, and 3 months to \<2 years). Except for PK and dose change, which is within each age group only.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive daprodustat for up to 52 weeks.
Drug: Daprodustat
Daprodustat will be administered up to Week 52.
Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAEs are defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other situations as per medical and scientific judgement of the Investigator.
Time frame: Up to 56 weeks
Number of Participants With Adverse Event of Special Interests (AESIs)
AESIs are AEs of scientific interest specific to the drug class as per investigator assessment. AESI included: Death, Myocardial Infarction (MI), stroke, Heart Failure (HF), thromboembolic events, thrombosis of vascular access, Thrombosis and/or tissue ischemia secondary to excessive erythropoiesis, New diagnosis of hypertension or worsening of existing hypertension, Cancer related mortality and tumor progression and recurrence, Esophageal and gastric erosions. Number of participants with any AESIs have been presented.
Time frame: Up to 56 weeks
Number of Participants With AEs Leading to Study Intervention Discontinuation
All AEs leading to study intervention discontinuation were collected. Number of participants with any AEs leading to study intervention discontinuation have been presented
Time frame: Up to 52 weeks
Change From Baseline in Hematology Parameter: Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Hematology Parameter: Reticulocytes/Erythrocytes
Blood samples were collected to analyze the hematology parameter: Reticulocytes/Erythrocytes. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Hematology Parameter: Erythrocytes
Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes and Platelet Count
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes and Platelet count. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN)
Blood samples were collected to analyze the clinical chemistry parameters: Calcium, Potassium, Sodium and BUN. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Clinical Chemistry Parameter: Creatinine
Blood samples were collected to analyze the clinical chemistry parameter: Creatinine. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)
Blood samples were collected to analyze the clinical chemistry parameters: ALT, ALP and AST. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48, and 52
Change From Baseline in Clinical Chemistry Parameters: Bilirubin and Direct Bilirubin
Blood samples were collected to analyze the clinical chemistry parameters: Bilirubin and Direct Bilirubin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48, and 52
Change From Baseline in Clinical Chemistry Parameter: Protein
Blood samples were collected to analyze the clinical chemistry parameter: Protein. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48, and 52
Change From Baseline in Clinical Chemistry Parameter: Ferritin
Blood samples were collected to analyze the clinical chemistry parameter: Ferritin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Clinical Chemistry Parameter: Transferrin Saturation
Blood samples were collected to analyze the clinical chemistry parameter: Transferrin saturation. Transferrin saturation is measured as a percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Clinical Chemistry Parameter: Estimated Glomerular Filtration Rate
Blood samples were collected to analyze the clinical chemistry parameter: Estimated Glomerular Filtration Rate. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio
Blood samples were collected to analyze the hematology parameter: Prothrombin International Normalized Ratio. It is used to assess the clotting ability of blood. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48, and 52
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Systolic and diastolic blood pressure (BP) were assessed using an appropriate size cuff preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Heart Rate (HR)
Heart rate (HR) were assessed using an appropriate size cuff preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Weight
Weight readings in kilogram (kg) were collected. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Height
Height readings in centimeters (cm) were collected. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Absolute Values of Hemoglobin (Hgb)
Blood samples were collected from all participants for measurement of Hgb values in grams per deciliter (g/dL). Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Hgb results of participants with intercurrent events were excluded from the summary.
Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change From Baseline in Hemoglobin (Hgb)
Blood samples were collected from all participants for measurement of Hgb values in g/dL. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Hgb results of participants with intercurrent events were excluded from the summary.
Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Number of Participants With Hgb Values Above, Below and Within the Target Range (10 to 12 g/dL)
Number of participants with Hgb values above, below, and within the target range (10 to 12 g/dL) were assessed. Baseline assessment was defined as the last non-missing value prior to the start date and time of the study drug (Day 1). Hgb results of participants with intercurrent events were excluded from the summary.
Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Change in Daprodustat Dose From Starting Dose at Each Study Time Point
Daprodustat dose was adjusted, if required, one step at a time in the range of 1 to 24 mg, to maintain the target range for Hgb between 10 to 12 g/dL. Dose change values of daprodustat from starting dose at each study time point were calculated as dose level at indicated time point minus starting dose at Day 1 (Baseline).
Time frame: Day 1 (Baseline), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Number of Participants With 0 to 10, or Greater Than (>) 10 Dose Adjustments
Number of participants who required daprodustat dose adjustments form the starting dose were assessed. Data were categorized for number of participants who required no dose change (0 times) to 10 times and \>10 times dose adjustments during the study.
Time frame: Up to Week 52
Daprodustat Dose at Each Study Time Point
Mean and standard deviation of daprodustat dose received by participants at each study time point has been presented.
Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Maximum Plasma Concentration (Cmax) of Daprodustat
Blood samples were collected for the plasma concentrations of daprodustat from which pharmacokinetic (PK) parameters were determined. Mean and standard deviation of daprodustat Cmax at steady state obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis).
Time frame: Day 1: 1, 2 and 6 hours Post-dose; Week 2: Pre-dose and 1, 2 and 6 hours Post-dose
Area Under the Curve (AUC) at Steady State of Daprodustat
Blood samples were collected for the plasma concentrations of daprodustat from which PK parameters were determined. Mean and standard deviation of daprodustat AUC at steady state obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis).
Time frame: Day 1: 1, 2 and 6 hours Post-dose; Week 2: Pre-dose and 1, 2 and 6 hours Post-dose
Plasma Concentrations of Daprodustat and Metabolites at Pre-dose (Ctrough)
Blood samples were collected for the plasma concentrations of daprodustat and metabolites from which PK parameters were determined. Mean and standard deviation of raw daprodustat and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401) at steady state at pre-dose obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis).
Time frame: Pre-dose on Week 2
Participants were enrolled into two sub-trials based on dialysis status under a master protocol. The non-dialysis (ND) sub-trial enrolled pediatric participants with anemia associated with chronic kidney disease (CKD) not yet requiring dialysis in non-US countries. The dialysis (D) sub-trial enrolled pediatric participants with anemia associated with CKD requiring dialysis in non-US countries. Recruitment was conducted separately for each sub-trial.
| Milestone | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Started | 2 | 2 |
| Completed | 1 | 2 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAEs are defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other situations as per medical and scientific judgement of the Investigator.
| Participants | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Any AEs | 2 | 2 |
| Any SAEs | 1 | 0 |
AESIs are AEs of scientific interest specific to the drug class as per investigator assessment. AESI included: Death, Myocardial Infarction (MI), stroke, Heart Failure (HF), thromboembolic events, thrombosis of vascular access, Thrombosis and/or tissue ischemia secondary to excessive erythropoiesis, New diagnosis of hypertension or worsening of existing hypertension, Cancer related mortality and tumor progression and recurrence, Esophageal and gastric erosions. Number of participants with any AESIs have been presented.
| Participants | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Number of Participants With Adverse Event of Special Interests (AESIs) | 0 | 0 |
All AEs leading to study intervention discontinuation were collected. Number of participants with any AEs leading to study intervention discontinuation have been presented
| Participants | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Number of Participants With AEs Leading to Study Intervention Discontinuation | 0 | 0 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Percentage of red blood cells in blood | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 4 | 0.0160 ± NA | 0.0030 ± 0.03818 |
| Week 8 | 0.0530 ± NA | 0.0025 ± 0.03889 |
| Week 12 | -0.0280 ± NA | 0.0135 ± 0.01485 |
| Week 16 | -0.0200 ± NA | -0.0185 ± 0.03889 |
| Week 20 | 0.0000 ± NA | -0.0005 ± 0.01909 |
| Week 24 | 0.0050 ± NA | 0.0060 ± 0.02687 |
| Week 28 | 0.0340 ± NA | -0.0050 ± 0.03536 |
| Week 32 | 0.0350 ± NA | 0.0370 ± NA |
| Week 36 | 0.0070 ± NA | 0.0095 ± 0.02333 |
| Week 40 | -0.0220 ± NA | 0.0270 ± 0.04667 |
| Week 44 | -0.0020 ± NA | -0.0060 ± 0.03677 |
| Week 48 | — | 0.0035 ± 0.01909 |
| Week 52 | -0.0320 ± NA | 0.0020 ± 0.01980 |
Blood samples were collected to analyze the hematology parameter: Reticulocytes/Erythrocytes. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Ratio of Reticulocytes to Erythrocytes | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 4 | 0.0080 ± NA | -0.0039 ± 0.00686 |
| Week 8 | -0.0020 ± NA | 0.0031 ± 0.00134 |
| Week 12 | 0.0060 ± NA | -0.0012 ± 0.00594 |
| Week 16 | 0.0100 ± NA | -0.0024 ± 0.00481 |
| Week 20 | 0.0110 ± NA | 0.0001 ± 0.00693 |
| Week 24 | 0.0060 ± NA | -0.0020 ± 0.00700 |
| Week 28 | 0.0040 ± NA | 0.0007 ± 0.00467 |
| Week 32 | 0.0030 ± NA | -0.0037 ± NA |
| Week 36 | 0.0020 ± NA | 0.0010 ± 0.00573 |
| Week 40 | 0.0070 ± NA | -0.0020 ± 0.00849 |
| Week 44 | 0.0100 ± NA | 0.0010 ± 0.00714 |
| Week 48 | — | 0.0026 ± 0.00771 |
| Week 52 | 0.0040 ± NA | 0.0018 ± 0.00453 |
Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Trillion cells per Liter (10^12 cells/L) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 4 | 0.130 ± NA | 0.060 ± 0.4243 |
| Week 8 | 0.480 ± NA | 0.045 ± 0.4313 |
| Week 12 | -0.350 ± NA | 0.060 ± 0.2546 |
| Week 16 | -0.350 ± NA | -0.280 ± 0.5374 |
| Week 20 | 0.010 ± NA | -0.050 ± 0.2970 |
| Week 24 | 0.030 ± NA | 0.025 ± 0.3889 |
| Week 28 | 0.250 ± NA | -0.095 ± 0.4879 |
| Week 32 | 0.350 ± NA | 0.350 ± NA |
| Week 36 | 0.030 ± NA | 0.050 ± 0.3111 |
| Week 40 | -0.330 ± NA | 0.310 ± 0.4808 |
| Week 44 | -0.260 ± NA | -0.080 ± 0.5515 |
| Week 48 | — | -0.025 ± 0.2758 |
| Week 52 | -0.490 ± NA | -0.050 ± 0.2687 |
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes and Platelet count. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Giga cells per Liter (10^9 cells/L) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Basophils: Week 4 | 0.0120 ± NA | 0.0007 ± 0.01509 |
| Basophils: Week 8 | -0.0177 ± NA | 0.0087 ± 0.01232 |
| Basophils: Week 12 | -0.0011 ± NA | 0.0093 ± 0.01312 |
| Basophils: Week 16 | -0.0062 ± NA | -0.0038 ± 0.02292 |
| Basophils: Week 20 | 0.0085 ± NA | 0.0162 ± 0.02295 |
| Basophils: Week 24 | -0.0044 ± NA | 0.0066 ± 0.02353 |
| Basophils: Week 28 | 0.0182 ± NA | 0.0003 ± 0.01458 |
| Basophils: Week 32 | -0.0209 ± NA | 0.0314 ± NA |
| Basophils: Week 36 | -0.0091 ± NA | 0.0051 ± 0.02139 |
| Basophils: Week 40 | -0.0020 ± NA | 0.0063 ± 0.00522 |
| Basophils: Week 44 | -0.0091 ± NA | 0.0001 ± 0.00017 |
| Basophils: Week 48 | — | 0.0059 ± 0.00833 |
| Basophils: Week 52 | 0.0012 ± NA | -0.0001 ± 0.00008 |
| Eosinophils: Week 4 | 0.0146 ± NA | 0.4193 ± 0.63542 |
| Eosinophils: Week 8 | -0.0962 ± NA | 0.2385 ± 0.30899 |
| Eosinophils: Week 12 | -0.0072 ± NA | 0.2547 ± 0.11973 |
| Eosinophils: Week 16 | 0.0239 ± NA | 0.1184 ± 0.15326 |
| Eosinophils: Week 20 | -0.0037 ± NA | 0.0989 ± 0.13988 |
| Eosinophils: Week 24 | 0.0203 ± NA | 0.0698 ± 0.18356 |
| Eosinophils: Week 28 | -0.0578 ± NA | 0.0238 ± 0.07607 |
| Eosinophils: Week 32 | -0.1571 ± NA | 0.2913 ± NA |
| Eosinophils: Week 36 | -0.0775 ± NA | 0.0395 ± 0.14069 |
| Eosinophils: Week 40 | -0.1208 ± NA | 0.0357 ± 0.07683 |
| Eosinophils: Week 44 | -0.0522 ± NA | 0.0395 ± 0.02754 |
| Eosinophils: Week 48 | — | 0.1645 ± 0.10537 |
| Eosinophils: Week 52 | -0.0628 ± NA | 0.0390 ± 0.00136 |
| Lymphocytes: Week 4 | 0.2799 ± NA | -0.2606 ± 0.01499 |
| Lymphocytes: Week 8 | 0.4370 ± NA | -0.4114 ± 0.49299 |
| Lymphocytes: Week 12 | -0.2165 ± NA | -0.2552 ± 0.57253 |
| Lymphocytes: Week 16 | -0.2907 ± NA | -0.2009 ± 0.40885 |
| Lymphocytes: Week 20 | 0.1325 ± NA | -0.3649 ± 0.58710 |
| Lymphocytes: Week 24 | -0.1535 ± NA | -0.3050 ± 0.58684 |
| Lymphocytes: Week 28 | 0.0289 ± NA | -0.2517 ± 0.50673 |
| Lymphocytes: Week 32 | -1.1501 ± NA | 0.6357 ± NA |
| Lymphocytes: Week 36 | 0.0581 ± NA | -0.4619 ± 1.00143 |
| Lymphocytes: Week 40 | -0.2134 ± NA | -0.4961 ± 0.05108 |
| Lymphocytes: Week 44 | 0.5638 ± NA | -0.4021 ± 0.50620 |
| Lymphocytes: Week 48 | — | -0.1701 ± 0.33923 |
| Lymphocytes: Week 52 | 0.4700 ± NA | -0.5256 ± 0.60026 |
| Monocytes: Week 4 | 0.0408 ± NA | -0.0318 ± 0.03079 |
| Monocytes: Week 8 | 0.1094 ± NA | 0.0230 ± 0.15981 |
| Monocytes: Week 12 | -0.0258 ± NA | 0.0536 ± 0.01924 |
| Monocytes: Week 16 | -0.0289 ± NA | 0.0148 ± 0.00684 |
| Monocytes: Week 20 | 0.0132 ± NA | -0.0307 ± 0.11217 |
| Monocytes: Week 24 | -0.0404 ± NA | -0.0310 ± 0.04098 |
| Monocytes: Week 28 | 0.0169 ± NA | -0.0314 ± 0.06868 |
| Monocytes: Week 32 | -0.2902 ± NA | 0.0410 ± NA |
| Monocytes: Week 36 | -0.0410 ± NA | -0.0596 ± 0.01360 |
| Monocytes: Week 40 | -0.0708 ± NA | 0.0884 ± 0.20985 |
| Monocytes: Week 44 | 0.0601 ± NA | -0.0110 ± 0.02690 |
| Monocytes: Week 48 | — | 0.0492 ± 0.04132 |
| Monocytes: Week 52 | 0.0164 ± NA | -0.0112 ± 0.01583 |
| Neutrophils: Week 4 | -0.1973 ± NA | -0.1626 ± 0.16602 |
| Neutrophils: Week 8 | -3.5926 ± NA | 0.4712 ± 1.43005 |
| Neutrophils: Week 12 | -0.1094 ± NA | 0.4876 ± 0.20136 |
| Neutrophils: Week 16 | -1.7681 ± NA | 1.3315 ± 1.27070 |
| Neutrophils: Week 20 | -0.8705 ± NA | -0.0296 ± 0.38241 |
| Neutrophils: Week 24 | -1.2919 ± NA | 0.2346 ± 0.30353 |
| Neutrophils: Week 28 | 1.6839 ± NA | -0.1160 ± 0.33096 |
| Neutrophils: Week 32 | -5.3517 ± NA | 1.1306 ± NA |
| Neutrophils: Week 36 | 1.2095 ± NA | 0.4269 ± 0.70272 |
| Neutrophils: Week 40 | -0.2730 ± NA | 1.0158 ± 0.85667 |
| Neutrophils: Week 44 | 0.5974 ± NA | 0.0185 ± 0.11095 |
| Neutrophils: Week 48 | — | 0.3055 ± 0.11948 |
| Neutrophils: Week 52 | -0.0248 ± NA | 0.6728 ± 0.91533 |
| Leukocytes: Week 4 | 0.150 ± NA | -0.045 ± 0.7849 |
| Leukocytes: Week 8 | -3.160 ± NA | 0.315 ± 2.4254 |
| Leukocytes: Week 12 | -0.360 ± NA | 0.510 ± 0.5798 |
| Leukocytes: Week 16 | -2.070 ± NA | 1.240 ± 0.6505 |
| Leukocytes: Week 20 | -0.720 ± NA | -0.315 ± 1.2516 |
| Leukocytes: Week 24 | -1.470 ± NA | -0.060 ± 1.1879 |
| Leukocytes: Week 28 | 1.690 ± NA | -0.385 ± 1.0112 |
| Leukocytes: Week 32 | -6.970 ± NA | 2.130 ± NA |
| Leukocytes: Week 36 | 1.140 ± NA | -0.070 ± 1.8809 |
| Leukocytes: Week 40 | -0.680 ± NA | 0.605 ± 0.9970 |
| Leukocytes: Week 44 | 1.160 ± NA | -0.390 ± 0.7212 |
| Leukocytes: Week 48 | — | 0.310 ± 0.4384 |
| Leukocytes: Week 52 | 0.400 ± NA | 0.170 ± 0.3253 |
| Platelet count: Week 4 | 16.0 ± NA | -30.0 ± 26.87 |
| Platelet count: Week 8 | -31.0 ± NA | -41.5 ± 34.65 |
| Platelet count: Week 12 | -11.0 ± NA | -32.0 ± 39.60 |
| Platelet count: Week 16 | -5.0 ± NA | -47.0 ± 14.14 |
| Platelet count: Week 20 | 5.0 ± NA | -39.5 ± 27.58 |
| Platelet count: Week 24 | -11.0 ± NA | -10.0 ± 7.07 |
| Platelet count: Week 28 | 10.0 ± NA | -14.5 ± 6.36 |
| Platelet count: Week 32 | 6.0 ± NA | 1.0 ± NA |
| Platelet count: Week 36 | -4.0 ± NA | -25.0 ± 0.00 |
| Platelet count: Week 40 | 23.0 ± NA | -18.5 ± 27.58 |
| Platelet count: Week 44 | 28.0 ± NA | -7.5 ± 37.48 |
| Platelet count: Week 48 | — | -36.0 ± 35.36 |
| Platelet count: Week 52 | 30.0 ± NA | 11.0 ± 65.05 |
Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Femtoliter (fL) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 4 | 1.00 ± NA | -0.45 ± 0.919 |
| Week 8 | 2.10 ± NA | -0.35 ± 0.919 |
| Week 12 | 1.00 ± NA | 2.00 ± 1.414 |
| Week 16 | 3.10 ± NA | 1.15 ± 1.344 |
| Week 20 | -0.20 ± NA | 0.85 ± 1.202 |
| Week 24 | 0.60 ± NA | 0.95 ± 1.202 |
| Week 28 | 2.60 ± NA | 0.70 ± 1.131 |
| Week 32 | 0.80 ± NA | 1.90 ± NA |
| Week 36 | 1.00 ± NA | 1.25 ± 0.495 |
| Week 40 | 2.10 ± NA | 0.35 ± 1.626 |
| Week 44 | 5.60 ± NA | 0.20 ± 1.980 |
| Week 48 | — | 1.35 ± 0.778 |
| Week 52 | 3.40 ± NA | 1.45 ± 0.495 |
Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Picogram (pg) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 4 | 0.30 ± NA | 0.00 ± 0.849 |
| Week 8 | 0.20 ± NA | 0.45 ± 0.071 |
| Week 12 | 0.70 ± NA | 0.70 ± 0.141 |
| Week 16 | 1.30 ± NA | 0.95 ± 0.212 |
| Week 20 | 0.90 ± NA | 0.85 ± 0.212 |
| Week 24 | 1.30 ± NA | 0.70 ± 0.000 |
| Week 28 | 1.20 ± NA | 1.45 ± 0.212 |
| Week 32 | 1.00 ± NA | 0.40 ± NA |
| Week 36 | 0.50 ± NA | 1.15 ± 0.636 |
| Week 40 | 1.60 ± NA | 0.55 ± 0.212 |
| Week 44 | 2.10 ± NA | 0.55 ± 1.061 |
| Week 48 | — | 0.80 ± 0.566 |
| Week 52 | 1.80 ± NA | 1.95 ± 1.626 |
Blood samples were collected to analyze the clinical chemistry parameters: Calcium, Potassium, Sodium and BUN. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| millimoles per liter (mmol/L) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Calcium: Week 4 | 0.0749 ± NA | -0.1123 ± 0.05293 |
| Calcium: Week 8 | -0.1248 ± NA | -0.1248 ± 0.10585 |
| Calcium: Week 12 | -0.0499 ± NA | -0.1372 ± 0.12350 |
| Calcium: Week 16 | 0.0000 ± NA | -0.1372 ± 0.12350 |
| Calcium: Week 20 | 0.0250 ± NA | -0.0873 ± 0.08821 |
| Calcium: Week 24 | 0.0250 ± NA | -0.0873 ± 0.15878 |
| Calcium: Week 28 | -0.0499 ± NA | -0.1871 ± 0.08821 |
| Calcium: Week 32 | 0.0250 ± NA | 0.0000 ± NA |
| Calcium: Week 36 | 0.1248 ± NA | -0.1372 ± 0.12350 |
| Calcium: Week 40 | 0.0000 ± NA | -0.0624 ± 0.05293 |
| Calcium: Week 44 | 0.1248 ± NA | -0.1248 ± 0.07057 |
| Calcium: Week 48 | — | -0.1123 ± 0.08821 |
| Calcium: Week 52 | 0.0998 ± NA | -0.1747 ± 0.14114 |
| Potassium: Week 4 | 0.40 ± NA | -0.35 ± 0.354 |
| Potassium: Week 8 | 0.30 ± NA | -0.40 ± 0.000 |
| Potassium: Week 12 | 0.40 ± NA | -0.30 ± 0.283 |
| Potassium: Week 16 | 0.10 ± NA | -0.45 ± 0.212 |
| Potassium: Week 20 | 0.30 ± NA | -0.10 ± 0.424 |
| Potassium: Week 24 | 0.20 ± NA | -0.05 ± 0.495 |
| Potassium: Week 28 | 0.30 ± NA | -0.55 ± 0.354 |
| Potassium: Week 32 | 0.30 ± NA | -0.30 ± NA |
| Potassium: Week 36 | 0.20 ± NA | -0.35 ± 0.071 |
| Potassium: Week 40 | 0.40 ± NA | -0.55 ± 0.354 |
| Potassium: Week 44 | 0.20 ± NA | -0.40 ± 0.424 |
| Potassium: Week 48 | — | -0.25 ± 0.495 |
| Potassium: Week 52 | 0.50 ± NA | -0.20 ± 0.283 |
| Sodium: Week 4 | 0.0 ± NA | 0.5 ± 3.54 |
| Sodium: Week 8 | 0.0 ± NA | -0.5 ± 0.71 |
| Sodium: Week 12 | -1.0 ± NA | 0.0 ± 0.00 |
| Sodium: Week 16 | 0.0 ± NA | 0.5 ± 3.54 |
| Sodium: Week 20 | 1.0 ± NA | -2.0 ± 2.83 |
| Sodium: Week 24 | 0.0 ± NA | 0.5 ± 2.12 |
| Sodium: Week 28 | -2.0 ± NA | -0.5 ± 3.54 |
| Sodium: Week 32 | 0.0 ± NA | -3.0 ± NA |
| Sodium: Week 36 | 0.0 ± NA | -0.5 ± 2.12 |
| Sodium: Week 40 | 0.0 ± NA | -2.5 ± 3.54 |
| Sodium: Week 44 | 1.0 ± NA | -0.5 ± 4.95 |
| Sodium: Week 48 | — | -1.0 ± 2.83 |
| Sodium: Week 52 | -1.0 ± NA | 0.5 ± 2.12 |
| BUN: Week 4 | 0.9996 ± NA | 0.0893 ± 3.40790 |
| BUN: Week 8 | -0.2142 ± NA | 2.1242 ± 4.06424 |
| BUN: Week 12 | 1.7136 ± NA | 0.6962 ± 2.54961 |
| BUN: Week 16 | 1.3923 ± NA | 0.1964 ± 4.77106 |
| BUN: Week 20 | 0.7854 ± NA | 0.8390 ± 0.83304 |
| BUN: Week 24 | 0.6069 ± NA | 0.0000 ± 3.02925 |
| BUN: Week 28 | 3.6057 ± NA | 0.0893 ± 2.90303 |
| BUN: Week 32 | 2.2134 ± NA | 1.4280 ± NA |
| BUN: Week 36 | 4.1055 ± NA | 0.4820 ± 1.33792 |
| BUN: Week 40 | -0.6426 ± NA | 4.1948 ± 7.19446 |
| BUN: Week 44 | 2.2848 ± NA | 1.1603 ± 2.90303 |
| BUN: Week 48 | — | 0.4463 ± 2.90303 |
| BUN: Week 52 | 1.9278 ± NA | 1.1424 ± 4.94777 |
Blood samples were collected to analyze the clinical chemistry parameter: Creatinine. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| micromoles per Liter (µmol/L) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 4 | 21.2160 ± NA | -3.0940 ± 5.62574 |
| Week 8 | 139.6720 ± NA | -0.4420 ± 9.37624 |
| Week 12 | -1.7680 ± NA | 3.9780 ± 10.62640 |
| Week 16 | 4.4200 ± NA | 14.5860 ± 19.37755 |
| Week 20 | -22.1000 ± NA | 12.3760 ± 6.25082 |
| Week 24 | -5.3040 ± NA | 24.3100 ± 26.87854 |
| Week 28 | 78.6760 ± NA | 13.7020 ± 13.12673 |
| Week 32 | 83.9800 ± NA | 48.6200 ± NA |
| Week 36 | 95.4720 ± NA | 32.2660 ± 45.63101 |
| Week 40 | 100.7760 ± NA | 65.4160 ± 75.00989 |
| Week 44 | 115.8040 ± NA | 49.5040 ± 57.50758 |
| Week 48 | — | 56.1340 ± 65.63365 |
| Week 52 | 151.1640 ± NA | 73.8140 ± 94.38744 |
Blood samples were collected to analyze the clinical chemistry parameters: ALT, ALP and AST. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| International units per liter | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| ALT: Week 4 | 2.0 ± NA | -2.0 ± 0.00 |
| ALT: Week 8 | 2.0 ± NA | -2.5 ± 0.71 |
| ALT: Week 12 | 2.0 ± NA | -3.5 ± 0.71 |
| ALT: Week 24 | 0.0 ± NA | -3.5 ± 2.12 |
| ALT: Week 32 | 1.0 ± NA | -5.0 ± NA |
| ALT: Week 36 | -1.0 ± NA | -1.0 ± 0.00 |
| ALT: Week 40 | -2.0 ± NA | -3.5 ± 2.12 |
| ALT: Week 48 | — | -0.5 ± 4.95 |
| ALT: Week 52 | 0.0 ± NA | -4.5 ± 0.71 |
| ALP: Week 4 | 34.0 ± NA | -29.0 ± NA |
| ALP: Week 8 | 13.0 ± NA | 77.0 ± NA |
| ALP: Week 12 | 31.0 ± NA | 123.0 ± NA |
| ALP: Week 24 | 36.0 ± NA | 23.0 ± NA |
| ALP: Week 32 | 29.0 ± NA | 141.0 ± NA |
| ALP: Week 36 | 14.0 ± NA | 113.0 ± NA |
| ALP: Week 40 | 2.0 ± NA | 100.0 ± NA |
| ALP: Week 48 | — | 35.0 ± NA |
| ALP: Week 52 | 2.0 ± NA | 46.0 ± NA |
| AST: Week 4 | 3.0 ± NA | -1.0 ± 1.41 |
| AST: Week 8 | 5.0 ± NA | -1.0 ± 1.41 |
| AST: Week 12 | 0.0 ± NA | -4.0 ± 2.83 |
| AST: Week 24 | -1.0 ± NA | -5.5 ± 3.54 |
| AST: Week 32 | 1.0 ± NA | -4.0 ± NA |
| AST: Week 36 | -2.0 ± NA | -2.5 ± 3.54 |
| AST: Week 40 | -3.0 ± NA | -4.0 ± 4.24 |
| AST: Week 48 | — | -4.5 ± 4.95 |
| AST: Week 52 | -2.0 ± NA | -6.0 ± 4.24 |
Blood samples were collected to analyze the clinical chemistry parameters: Bilirubin and Direct Bilirubin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| micromoles per Liter (µmol/L) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Bilirubin: Week 4 | 0.0000 ± NA | 1.1115 ± 1.57190 |
| Bilirubin: Week 8 | 0.0000 ± NA | 1.5390 ± 2.17647 |
| Bilirubin: Week 12 | 0.0000 ± NA | 3.4200 ± 4.83661 |
| Bilirubin: Week 24 | -1.7100 ± NA | 4.9590 ± 2.17647 |
| Bilirubin: Week 32 | 0.0000 ± NA | 3.4200 ± NA |
| Bilirubin: Week 36 | 0.0000 ± NA | 1.9665 ± 0.36275 |
| Bilirubin: Week 40 | 0.0000 ± NA | 3.5910 ± 0.24183 |
| Bilirubin: Week 48 | — | -0.3420 ± 0.48366 |
| Bilirubin: Week 52 | -1.7100 ± NA | 1.6245 ± 2.29739 |
| Direct Bilirubin: Week 4 | 0.0000 ± NA | 0.0000 ± 0.00000 |
| Direct Bilirubin: Week 8 | 0.0000 ± NA | 0.1710 ± 0.24183 |
| Direct Bilirubin: Week 12 | 0.0000 ± NA | 0.4275 ± 0.60458 |
| Direct Bilirubin: Week 24 | 0.0000 ± NA | 0.4275 ± 0.60458 |
| Direct Bilirubin: Week 32 | 0.0000 ± NA | 0.0000 ± NA |
| Direct Bilirubin: Week 36 | 0.0000 ± NA | 0.0855 ± 0.12092 |
| Direct Bilirubin: Week 40 | 0.0000 ± NA | 0.0000 ± 0.00000 |
| Direct Bilirubin: Week 48 | — | 0.0855 ± 0.12092 |
| Direct Bilirubin: Week 52 | 0.0000 ± NA | 0.0855 ± 0.12092 |
Blood samples were collected to analyze the clinical chemistry parameter: Protein. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Grams per liter | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 4 | 6.00 ± NA | -2.30 ± 1.838 |
| Week 8 | 5.00 ± NA | -1.85 ± 1.202 |
| Week 12 | -1.00 ± NA | -2.65 ± 0.495 |
| Week 24 | 2.00 ± NA | -1.45 ± 2.051 |
| Week 32 | 4.00 ± NA | 2.00 ± NA |
| Week 36 | 6.00 ± NA | -1.65 ± 3.748 |
| Week 40 | 3.00 ± NA | 2.25 ± 5.303 |
| Week 48 | — | 0.10 ± 2.687 |
| Week 52 | 3.00 ± NA | -0.65 ± 2.333 |
Blood samples were collected to analyze the clinical chemistry parameter: Ferritin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| micrograms per liter (µg/L) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 4 | -32.00 ± NA | -12.60 ± 20.365 |
| Week 8 | 167.00 ± NA | -17.30 ± 12.304 |
| Week 12 | 28.00 ± NA | -23.30 ± 19.375 |
| Week 16 | -29.00 ± NA | -24.95 ± 9.970 |
| Week 20 | -35.00 ± NA | -28.50 ± 13.435 |
| Week 24 | -33.00 ± NA | -26.95 ± 22.698 |
| Week 28 | -36.00 ± NA | -27.65 ± 25.951 |
| Week 32 | -14.00 ± NA | -22.00 ± NA |
| Week 36 | 42.00 ± NA | -31.00 ± 12.728 |
| Week 40 | 42.00 ± NA | -9.60 ± 37.335 |
| Week 44 | 75.00 ± NA | -3.00 ± 59.397 |
| Week 48 | — | -16.30 ± 50.487 |
| Week 52 | 39.00 ± NA | -5.05 ± 56.498 |
Blood samples were collected to analyze the clinical chemistry parameter: Transferrin saturation. Transferrin saturation is measured as a percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Percentage (%) of transferrin saturation | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 4 | -6.900 ± NA | -14.990 ± 43.8548 |
| Week 8 | -2.300 ± NA | 6.385 ± 7.6155 |
| Week 12 | 6.500 ± NA | -18.245 ± 68.9500 |
| Week 16 | -0.900 ± NA | -2.775 ± 4.5608 |
| Week 20 | -3.600 ± NA | -18.500 ± 55.8614 |
| Week 24 | -7.770 ± NA | -12.995 ± 55.1614 |
| Week 28 | -6.900 ± NA | -29.050 ± 56.4978 |
| Week 32 | -8.100 ± NA | -69.000 ± NA |
| Week 36 | 3.100 ± NA | -31.620 ± 62.7628 |
| Week 40 | 3.100 ± NA | -32.230 ± 52.0006 |
| Week 44 | -7.600 ± NA | -27.305 ± 27.8529 |
| Week 48 | — | -25.715 ± 28.6873 |
| Week 52 | -1.500 ± NA | -7.520 ± 51.5905 |
Blood samples were collected to analyze the clinical chemistry parameter: Estimated Glomerular Filtration Rate. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| mL per minute per 1.73 square meter | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 4 | -0.380 ± NA | 0.615 ± 0.7990 |
| Week 8 | -2.020 ± NA | -0.310 ± 2.4042 |
| Week 12 | 0.040 ± NA | -1.095 ± 3.0335 |
| Week 16 | -0.060 ± NA | -1.530 ± 2.0365 |
| Week 20 | 0.440 ± NA | -1.740 ± 0.3253 |
| Week 24 | 0.130 ± NA | -2.655 ± 2.3405 |
| Week 28 | -0.930 ± NA | -1.200 ± 1.2445 |
| Week 32 | -1.320 ± NA | -4.650 ± NA |
| Week 36 | -1.460 ± NA | -2.370 ± 5.1053 |
| Week 40 | -1.580 ± NA | -6.565 ± 4.3346 |
| Week 44 | -1.770 ± NA | -4.855 ± 4.0800 |
| Week 48 | — | -5.410 ± 4.4548 |
| Week 52 | -2.260 ± NA | -5.935 ± 6.6539 |
Blood samples were collected to analyze the hematology parameter: Prothrombin International Normalized Ratio. It is used to assess the clotting ability of blood. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Ratio | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 4 | -0.010 ± NA | -0.010 ± NA |
| Week 8 | -0.040 ± NA | 0.050 ± NA |
| Week 12 | 0.010 ± NA | 0.030 ± NA |
| Week 24 | -0.040 ± NA | 0.010 ± NA |
| Week 32 | -0.010 ± NA | — |
| Week 36 | 0.010 ± NA | -0.020 ± NA |
| Week 40 | 0.030 ± NA | 0.010 ± NA |
| Week 48 | — | -0.010 ± NA |
| Week 52 | 0.030 ± NA | 0.040 ± NA |
Systolic and diastolic blood pressure (BP) were assessed using an appropriate size cuff preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| millimeters of mercury (mmHg) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| SBP: Week 2 | 11.5 ± 9.19 | -8.0 ± 11.31 |
| SBP: Week 4 | 9.0 ± NA | 3.5 ± 7.78 |
| SBP: Week 8 | 6.0 ± NA | -0.5 ± 16.26 |
| SBP: Week 12 | 0.0 ± NA | -9.5 ± 7.78 |
| SBP: Week 16 | 2.0 ± NA | -8.5 ± 2.12 |
| SBP: Week 20 | 8.0 ± NA | -7.5 ± 9.19 |
| SBP: Week 24 | 25.0 ± NA | -7.0 ± 2.83 |
| SBP: Week 28 | 17.0 ± NA | 0.0 ± 19.80 |
| SBP: Week 32 | 20.0 ± NA | 20.0 ± NA |
| SBP: Week 36 | 16.0 ± NA | 2.5 ± 14.85 |
| SBP: Week 40 | 10.0 ± NA | -1.0 ± 28.28 |
| SBP: Week 44 | 7.0 ± NA | -5.5 ± 0.71 |
| SBP: Week 48 | — | 4.0 ± 29.70 |
| SBP: Week 52 | 4.0 ± NA | 0.0 ± 16.97 |
| DBP: Week 2 | 3.5 ± 2.12 | -7.5 ± 3.54 |
| DBP: Week 4 | 19.0 ± NA | 2.5 ± 14.85 |
| DBP: Week 8 | 8.0 ± NA | -3.0 ± 2.83 |
| DBP: Week 12 | -4.0 ± NA | -1.0 ± 1.41 |
| DBP: Week 16 | 5.0 ± NA | -8.0 ± 0.00 |
| DBP: Week 20 | 4.0 ± NA | -10.0 ± 9.90 |
| DBP: Week 24 | 16.0 ± NA | -4.5 ± 10.61 |
| DBP: Week 28 | 6.0 ± NA | 4.0 ± 8.49 |
| DBP: Week 32 | 8.0 ± NA | 7.0 ± NA |
| DBP: Week 36 | 11.0 ± NA | 5.0 ± 4.24 |
| DBP: Week 40 | 2.0 ± NA | 0.0 ± 5.66 |
| DBP: Week 44 | 11.0 ± NA | 4.5 ± 0.71 |
| DBP: Week 48 | — | -2.0 ± 0.00 |
| DBP: Week 52 | 1.0 ± NA | -6.0 ± 1.41 |
Heart rate (HR) were assessed using an appropriate size cuff preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| beats per minute (bpm) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 2 | -12.5 ± 9.19 | -9.0 ± 4.24 |
| Week 4 | 2.0 ± NA | -2.0 ± 18.38 |
| Week 8 | 15.0 ± NA | -8.0 ± 28.28 |
| Week 12 | 5.0 ± NA | -11.0 ± 43.84 |
| Week 16 | -10.0 ± NA | -12.0 ± 14.14 |
| Week 20 | 0.0 ± NA | 4.0 ± 14.14 |
| Week 24 | 8.0 ± NA | 5.5 ± 6.36 |
| Week 28 | 14.0 ± NA | 3.0 ± 5.66 |
| Week 32 | 11.0 ± NA | -12.0 ± NA |
| Week 36 | 1.00 ± NA | 3.5 ± 7.78 |
| Week 40 | -1.0 ± NA | 30.0 ± NA |
| Week 44 | 12.0 ± NA | -3.5 ± 12.02 |
| Week 48 | — | -17.5 ± 14.85 |
| Week 52 | -3.0 ± NA | 3.0 ± 1.41 |
Weight readings in kilogram (kg) were collected. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| kilograms (Kg) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 2 | -1.00 ± 0.141 | -0.70 ± 0.566 |
| Week 4 | -1.80 ± NA | -0.25 ± 1.485 |
| Week 8 | -2.40 ± NA | 0.40 ± 0.141 |
| Week 12 | 1.20 ± NA | 1.00 ± 0.566 |
| Week 16 | -0.50 ± NA | 0.60 ± 0.283 |
| Week 20 | 2.20 | 0.70 ± 0.849 |
| Week 24 | 2.00 ± NA | 0.45 ± 0.212 |
| Week 28 | 1.70 ± NA | 0.80 ± 0.990 |
| Week 32 | 1.00 ± NA | 1.90 ± NA |
| Week 36 | 0.20 ± NA | 0.95 ± 1.768 |
| Week 40 | 0.80 ± NA | 0.95 ± 1.061 |
| Week 44 | 1.50 ± NA | 1.85 ± 0.495 |
| Week 48 | — | 2.90 ± 0.000 |
| Week 52 | 1.30 ± NA | 2.70 ± 0.000 |
Height readings in centimeters (cm) were collected. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| centimeters (cm) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 2 | -1.50 ± 2.121 | 0.85 ± 1.202 |
| Week 4 | 0.00 ± NA | 0.95 ± 0.495 |
| Week 8 | 0.00 ± NA | 1.20 ± 0.707 |
| Week 12 | 0.00 ± NA | 2.65 ± 0.071 |
| Week 16 | 0.10 ± NA | 1.85 ± 1.485 |
| Week 20 | 0.30 ± NA | 3.35 ± 0.495 |
| Week 24 | 0.30 ± NA | 3.70 ± 0.707 |
| Week 28 | 1.00 ± NA | 4.60 ± 0.141 |
| Week 32 | 0.80 ± NA | 5.30 ± NA |
| Week 36 | 0.50 ± NA | 5.00 ± 1.131 |
| Week 40 | 0.20 ± NA | 4.50 ± 2.546 |
| Week 44 | 0.20 ± NA | 5.65 ± 2.192 |
| Week 48 | — | 5.65 ± 2.192 |
| Week 52 | -0.70 ± NA | 6.25 ± 2.333 |
Blood samples were collected from all participants for measurement of Hgb values in grams per deciliter (g/dL). Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Hgb results of participants with intercurrent events were excluded from the summary.
| grams per deciliter | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Baseline (Day 1) | 11.00 ± 0.424 | 11.35 ± 0.919 |
| Week 2 | 10.85 ± 1.061 | 11.90 ± 0.990 |
| Week 4 | 11.80 ± NA | 11.50 ± 0.566 |
| Week 8 | — | 11.65 ± 0.212 |
| Week 12 | — | 11.80 ± 0.283 |
| Week 16 | — | 10.95 ± 0.495 |
| Week 20 | — | 11.55 ± 0.212 |
| Week 24 | — | 11.70 ± 0.141 |
| Week 28 | — | 11.65 ± 0.354 |
| Week 32 | — | 11.80 ± NA |
| Week 36 | — | 11.95 ± 0.354 |
| Week 40 | — | 12.10 ± NA |
| Week 44 | — | 11.20 ± NA |
| Week 48 | — | 11.90 ± NA |
| Week 52 | — | 12.60 ± NA |
Blood samples were collected from all participants for measurement of Hgb values in g/dL. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Hgb results of participants with intercurrent events were excluded from the summary.
| grams per Liter | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 2 | -0.15 ± 0.636 | 0.55 ± 0.071 |
| Week 4 | 0.5 ± NA | 0.15 ± 1.485 |
| Week 8 | — | 0.30 ± 1.131 |
| Week 12 | — | 0.45 ± 0.636 |
| Week 16 | — | -0.40 ± 1.414 |
| Week 20 | — | 0.20 ± 0.707 |
| Week 24 | — | 0.35 ± 1.061 |
| Week 28 | — | 0.30 ± 1.273 |
| Week 32 | — | 1.10 ± NA |
| Week 36 | — | 0.60 ± 0.566 |
| Week 40 | — | 0.10 ± NA |
| Week 44 | — | -0.80 ± NA |
| Week 48 | — | -0.10 ± NA |
| Week 52 | — | 0.60 ± NA |
Number of participants with Hgb values above, below, and within the target range (10 to 12 g/dL) were assessed. Baseline assessment was defined as the last non-missing value prior to the start date and time of the study drug (Day 1). Hgb results of participants with intercurrent events were excluded from the summary.
| Participants | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Baseline (Day 1) — Above Target Range | 0 | 0 |
| Baseline (Day 1) — Within Target Range | 2 | 2 |
| Baseline (Day 1) — Below Target Range | 0 | 0 |
| Week 2 — Above Target Range | 0 | 1 |
| Week 2 — Within Target Range | 2 | 1 |
| Week 2 — Below Target Range | 0 | 0 |
| Week 4 — Above Target Range | 0 | 0 |
| Week 4 — Within Target Range | 1 | 2 |
| Week 4 — Below Target Range | 0 | 0 |
| Week 8 — Above Target Range | — | 0 |
| Week 8 — Within Target Range | — | 2 |
| Week 8 — Below Target Range | — | 0 |
| Week 12 — Above Target Range | — | 0 |
| Week 12 — Within Target Range | — | 2 |
| Week 12 — Below Target Range | — | 0 |
| Week 16 — Above Target Range | — | 0 |
| Week 16 — Within Target Range | — | 2 |
| Week 16 — Below Target Range | — | 0 |
| Week 20 — Above Target Range | — | 0 |
| Week 20 — Within Target Range | — | 2 |
| Week 20 — Below Target Range | — | 0 |
| Week 24 — Above Target Range | — | 0 |
| Week 24 — Within Target Range | — | 2 |
| Week 24 — Below Target Range | — | 0 |
| Week 28 — Above Target Range | — | 0 |
| Week 28 — Within Target Range | — | 2 |
| Week 28 — Below Target Range | — | 0 |
| Week 32 — Above Target Range | — | 0 |
| Week 32 — Within Target Range | — | 1 |
| Week 32 — Below Target Range | — | 0 |
| Week 36 — Above Target Range | — | 1 |
| Week 36 — Within Target Range | — | 1 |
| Week 36 — Below Target Range | — | 0 |
| Week 40 — Above Target Range | — | 1 |
| Week 40 — Within Target Range | — | 0 |
| Week 40 — Below Target Range | — | 0 |
| Week 44 — Above Target Range | — | 0 |
| Week 44 — Within Target Range | — | 1 |
| Week 44 — Below Target Range | — | 0 |
| Week 48 — Above Target Range | — | 0 |
| Week 48 — Within Target Range | — | 1 |
| Week 48 — Below Target Range | — | 0 |
| Week 52 — Above Target Range | — | 1 |
| Week 52 — Within Target Range | — | 0 |
| Week 52 — Below Target Range | — | 0 |
Daprodustat dose was adjusted, if required, one step at a time in the range of 1 to 24 mg, to maintain the target range for Hgb between 10 to 12 g/dL. Dose change values of daprodustat from starting dose at each study time point were calculated as dose level at indicated time point minus starting dose at Day 1 (Baseline).
| milligrams | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Week 2 | 0 ± 0 | -1 ± 1.41 |
| Week 4 | 0 ± NA | -0.5 ± 0.71 |
| Week 8 | -6 ± NA | -0.5 ± 0.71 |
| Week 12 | -2 ± NA | -0.5 ± 0.71 |
| Week 16 | 0 ± NA | -0.5 ± 0.71 |
| Week 20 | 0 ± NA | -0.5 ± 0.71 |
| Week 24 | 0 ± NA | -0.5 ± 0.71 |
| Week 28 | -2 ± NA | -0.5 ± 0.71 |
| Week 32 | -6 ± NA | 0 ± NA |
| Week 36 | -4 ± NA | -1 ± 1.41 |
| Week 40 | -4 ± NA | -2 ± 0 |
| Week 44 | -4 ± NA | -1 ± 0 |
| Week 48 | — | -1 ± NA |
Number of participants who required daprodustat dose adjustments form the starting dose were assessed. Data were categorized for number of participants who required no dose change (0 times) to 10 times and \>10 times dose adjustments during the study.
| Participants | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| No dose change (0 time) | 1 | 0 |
| 1 time | 0 | 0 |
| 2 times | 0 | 1 |
| 3 times | 0 | 0 |
| 4 times | 0 | 0 |
| 5 times | 0 | 0 |
| 6 times | 1 | 1 |
| 7 times | 0 | 0 |
| 8 times | 0 | 0 |
| 9 times | 0 | 0 |
| 10 times | 0 | 0 |
| >10 times | 0 | 0 |
Mean and standard deviation of daprodustat dose received by participants at each study time point has been presented.
| milligrams | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Baseline (Day 1) | 6.0 ± 0.00 | 2.0 ± 0.00 |
| Week 2 | 6.0 ± 0.00 | 1.0 ± 1.41 |
| Week 4 | 6.0 ± NA | 1.5 ± 0.71 |
| Week 8 | 0.0 ± NA | 1.5 ± 0.71 |
| Week 12 | 4.0 ± NA | 1.5 ± 0.71 |
| Week 16 | 6.0 ± NA | 1.5 ± 0.71 |
| Week 20 | 6.0 ± NA | 1.5 ± 0.71 |
| Week 24 | 6.00 ± NA | 1.5 ± 0.71 |
| Week 28 | 4.0 ± NA | 1.5 ± 0.71 |
| Week 32 | 0.0 ± NA | 2.0 ± NA |
| Week 36 | 2.0 ± NA | 1.0 ± 1.41 |
| Week 40 | 2.0 ± NA | 0.0 ± 0.00 |
| Week 44 | 2.0 ± NA | 1.0 ± 0.00 |
| Week 48 | — | 1.0 ± NA |
Blood samples were collected for the plasma concentrations of daprodustat from which pharmacokinetic (PK) parameters were determined. Mean and standard deviation of daprodustat Cmax at steady state obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis).
| Nanograms per milliliters (ng/mL) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Daprodustat | 115.047 ± 3.854 | 19.447 ± 10.770 |
Blood samples were collected for the plasma concentrations of daprodustat from which PK parameters were determined. Mean and standard deviation of daprodustat AUC at steady state obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis).
| Hours*nanogram per milliliter (h*ng/mL) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Area Under the Curve (AUC) at Steady State of Daprodustat | 185.379 ± 8.661 | 56.634 ± 6.009 |
Blood samples were collected for the plasma concentrations of daprodustat and metabolites from which PK parameters were determined. Mean and standard deviation of raw daprodustat and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401) at steady state at pre-dose obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis).
| Nanograms per milliliters (ng/mL) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Daprodustat | 0.4995 ± 0.3698 | NA ± NA |
| GSK2391220 | 6.540 ± 2.206 | NA ± NA |
| GSK2487818 | 0.869 ± 0.137 | NA ± NA |
| GSK2506102 | 3.040 ± 0.424 | NA ± NA |
| GSK2506104 | 10.55 ± 3.18 | 0.143 ± NA |
| GSK2531398 | 2.490 ± 0.184 | NA ± NA |
| GSK2531401 | 11.25 ± 1.48 | 0.127 ± NA |
Collected over All-cause mortality, serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected up to 56 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants Requiring Dialysis (D) | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Participants Not Yet Requiring Dialysis (ND) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| Congenital uterine anomalyCongenital, familial and genetic disorders | 1/2 | 0/2 |
| Retroperitoneal haematomaGastrointestinal disorders | 1/2 | 0/2 |
| HypertensionVascular disorders | 1/2 | 0/2 |
| Event | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) |
|---|---|---|
| NasopharyngitisInfections and infestations | 0/2 | 1/2 |
| Foot fractureInjury, poisoning and procedural complications | 0/2 | 1/2 |
| COVID-19Infections and infestations | 0/2 | 1/2 |
| HypertensionVascular disorders | 1/2 | 0/2 |
| Serum ferritin increasedInvestigations | 1/2 | 0/2 |
| Age, Customized(Participants) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) | Total |
|---|---|---|---|
| 12 to <18 years | 2 | 2 | 4 |
| Sex: Female, Male(Participants) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) | Total |
|---|---|---|---|
| Female | 2 | 0 | 2 |
| Male | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Participants Requiring Dialysis (D) | Participants Not Yet Requiring Dialysis (ND) | Total |
|---|---|---|---|
| All Other Races | 2 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
Ran from Sep 2023 to primary completion in Oct 2024, 13 months.
Results were first posted in Nov 2025, 1 year after primary completion.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 13 months is below that.
Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863